United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2015_register executive 2015-03-27 article Notices D09002ee1c7f7c71c D09002ee1c7f7c7ba United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a start-up exclusive commercial patent license agreement to practice the inventions embodied in U.S. provisional patent application no. 61/909,414 (NIH Ref. No. E- 011-2014/0-US-01) filed November 27, 2013; International PCT application no. PCT/US2014/066680 (NIH Ref. No. E-011-2014/0-PCT-02) filed November 20, 2014; Taiwanese patent application no. 103141004 (NIH Ref. No. E-011-2014/0-TW-03) filed November 26, 2014; and U.S. provisional patent application no. 62/011,462 (NIH Ref. No. E-161-2014/ 0-US-01) filed June 12, 2014; all entitled, "Heterocyclic Compounds and Methods of Use Thereof;" and all continuing applications and foreign counterparts to Virotas Biopharmaceuticals, LLC, a company having a place of business in California. The patent rights in these inventions have (a) been assigned to the United States of America, as represented by the Secretary, Department of Health and Human Services who has delegated authority for the licensing of inventions to the National Institutes of Health or (b) been exclusively licensed to the National Institutes of Health. The prospective exclusive license territory may be "worldwide", and the field of use may be limited to the following: "Prevention and treatment of Hepatitis C Virus infection." 80 FR 16389 https://www.govinfo.gov/app/details/FR-2015-03-27/2015-06974 2015-06974 fr27mr15-57 4140-01-P https://www.govinfo.gov/app/details/FR-2015-03-27/2015-06974 https://www.govinfo.gov/content/pkg/FR-2015-03-27/html/2015-06974.htm https://www.govinfo.gov/content/pkg/FR-2015-03-27/pdf/2015-06974.pdf 2 p. 16389 16390 80 FR 16389 Prospective Grant of Exclusive License: Small Molecule Therapeutics Against Hepatitis C Virus Infection; Federal Register Vol. 80, Issue NOTICE 2015-06974 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2015-04-13 4140-01-P 2015-06974 Notice.

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a start-up exclusive commercial patent license agreement to practice the inventions embodied in U.S. provisional patent application no. 61/909,414 (NIH Ref. No. E- 011-2014/0-US-01) filed November 27, 2013; International PCT application no. PCT/US2014/066680 (NIH Ref. No. E-011-2014/0-PCT-02) filed November 20, 2014; Taiwanese patent application no. 103141004 (NIH Ref. No. E-011-2014/0-TW-03) filed November 26, 2014; and U.S. provisional patent application no. 62/011,462 (NIH Ref. No. E-161-2014/ 0-US-01) filed June 12, 2014; all entitled, "Heterocyclic Compounds and Methods of Use Thereof;" and all continuing applications and foreign counterparts to Virotas Biopharmaceuticals, LLC, a company having a place of business in California. The patent rights in these inventions have (a) been assigned to the United States of America, as represented by the Secretary, Department of Health and Human Services who has delegated authority for the licensing of inventions to the National Institutes of Health or (b) been exclusively licensed to the National Institutes of Health. The prospective exclusive license territory may be "worldwide", and the field of use may be limited to the following: "Prevention and treatment of Hepatitis C Virus infection."

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 13, 2015 will be considered. Prospective Grants of Exclusive Licenses: Small Molecule Therapeutics Against Hepatitis C Virus Infection , changke@mail.nih.gov Vol. 80, no. 59 Office of the Federal Register, National Archives and Records Administration 2015-03-27 continuing daily deposited born digital 309 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2015-03-27 P0b002ee18be249ba 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr27mr15 https://www.govinfo.gov/app/details/FR-2015-03-27 https://www.govinfo.gov/content/pkg/FR-2015-03-27/pdf/FR-2015-03-27.pdf https://www.govinfo.gov/content/pkg/FR-2015-03-27/xml/FR-2015-03-27.xml fdlp 16249 16545 DGPO 2015-03-27 2024-06-02 FR-2015-03-27 machine generated eng FR FR-2015-03-27 80 59